Probiotics Improve Health Young Volunteers' Gut Microbiota

Not Applicable

Completed

• Conditions: Gastrointestinal Diseases

• Registration Number: NCT06196892
• Lead Sponsor: Wecare Probiotics Co., Ltd.

Brief Summary

The goal of this clinical trial is to evaluate whether daily supplementation with the probiotic Bifidobacterium breve BBr60 can improve metabolic, gastrointestinal, and emotional health in healthy adult volunteers aged 19 to 45 years.

The main questions it aims to answer are: Can B. breve BBr60 improve lipid metabolism (e.g., increase HDL and reduce total cholesterol) in healthy adults? Can B. breve BBr60 alleviate gastrointestinal symptoms and improve emotional well-being in a non-clinical population? Researchers will compare a BBr60 supplementation group to a placebo group to see if the probiotic group experiences greater improvements in metabolic, gastrointestinal, and psychological indicators.

Participants will: Take one sachet daily of either B. breve BBr60 (10 billion CFU) or placebo for 8 weeks. Provide blood and stool samples at baseline and week 8. Complete validated questionnaires assessing alcohol dependence, gastrointestinal symptoms, and emotional status.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-12-24
• Study First Submitted QC: 2023-12-24
• Study First Posted: 2024-01-09
• Study Start: 2024-04-20
• Status Verified: 2024-07
• Primary Completion: 2024-07-25
• Study Completion: 2024-07-26
• Last Update Submitted: 2025-06-10
• Last Update Posted: 2025-06-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 109

Inclusion Criteria

1. Aged 19-45 years;
2. Willing to voluntarily agree to and comply with the trial protocol, and capable of timely participation in screening and follow-up;
3. Have not suffered from gastrointestinal diseases in the past month;
4. Have not taken antibiotics in the past month.

Exclusion Criteria

1. Individuals under 19 or over 45 years of age, with an allergic constitution or allergy to any component of the test substance, symptoms of alcohol allergy, and pregnant or breastfeeding women;
2. Those who experience discomfort such as diarrhea or bloating after taking the test substance;
3. Patients with serious diseases of the cardiovascular, liver, kidney, hematopoietic systems, autoimmune diseases, endocrine disorders, mental illnesses, existing high blood sugar, or unhealthy gastrointestinal conditions;
4. Those who discontinue the test sample or take other medications midway, making it difficult to judge efficacy or with incomplete data;
5. Recently taken probiotics, prebiotics, or antibiotics related to the function of the test substance, affecting the judgment of results;
6. Individuals with a daily diet that is either too light or too greasy; those with special dietary structures due to weight loss or other reasons (such as a ketogenic diet);
7. Individuals with low body fat, BMI < 23.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Changes in intestinal flora	8 weeks	Collect patient fecal samples, test for 16S rRNA

Trial Locations

Locations (1)

Kang Zou; 🇨🇳 Nanjing, None Selected, China